BACKGROUND Company: Small pharmaceutical company Indication: Herpes zoster (shingles) Phase: III CHALLENGE Eight weeks before the first patient’s initial visit, the FDA asked the sponsor to add an imaging endpoint to the clinical trial, with imaging at baseline, days 1-8 and days 15, 30 and 45. The elderly patient population would struggle to comply with the number and frequency of imaging visits, and as a result, subject enrollment and retention would likely suffer. Also, this last minute request placed the study’s initiation timeline in jeopardy. The sponsor engaged ERT to quickly configure and deploy our imaging services and technology, which have been used to rescue failing studies or to meet very aggressive study initiation timelines. Imaging technology that delivers results wi

Join for free to read